Trials / Completed
CompletedNCT00500760
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
A Phase 2, Randomized Trial of Chemoradiation With or Without Panitumumab in Subjects With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 153 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The addition of chemotherapy to radiotherapy (chemoradiation) has improved outcomes for patients with locally advanced squamous cell carcinoma of the head and neck but additional improvements to treatment regimens are needed. The study is investigating if the addition of a targeted therapy (panitumumab) can improve the efficacy of chemoradiation without adding unmanageable toxicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cisplatin | Administered intravenously (IV; in a vein) |
| RADIATION | Standard Fractionation Radiotherapy | 70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions) |
| DRUG | Panitumumab | Administered intravenously |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2011-03-29
- Completion
- 2011-04-26
- First posted
- 2007-07-13
- Last updated
- 2018-10-17
- Results posted
- 2014-08-05
Source: ClinicalTrials.gov record NCT00500760. Inclusion in this directory is not an endorsement.